US10821150B2 - Infant nutrition for improvement in insulin sensitivity later in life - Google Patents
Infant nutrition for improvement in insulin sensitivity later in life Download PDFInfo
- Publication number
- US10821150B2 US10821150B2 US15/100,427 US201415100427A US10821150B2 US 10821150 B2 US10821150 B2 US 10821150B2 US 201415100427 A US201415100427 A US 201415100427A US 10821150 B2 US10821150 B2 US 10821150B2
- Authority
- US
- United States
- Prior art keywords
- casein
- nutritional composition
- infant
- whey
- diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010022489 Insulin Resistance Diseases 0.000 title claims description 32
- 230000006872 improvement Effects 0.000 title description 2
- 235000021125 infant nutrition Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 144
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 113
- 239000005018 casein Substances 0.000 claims abstract description 112
- 235000021240 caseins Nutrition 0.000 claims abstract description 112
- 235000016709 nutrition Nutrition 0.000 claims abstract description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 24
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 23
- 235000005911 diet Nutrition 0.000 claims description 74
- 230000037213 diet Effects 0.000 claims description 73
- 235000018102 proteins Nutrition 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 29
- 235000013350 formula milk Nutrition 0.000 claims description 25
- 230000002293 adipogenic effect Effects 0.000 claims description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 9
- 239000011707 mineral Substances 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 8
- 206010033307 Overweight Diseases 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 206010056997 Impaired fasting glucose Diseases 0.000 claims description 5
- 235000012631 food intake Nutrition 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 206010027525 Microalbuminuria Diseases 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 208000004104 gestational diabetes Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 abstract description 13
- 108010076119 Caseins Proteins 0.000 description 109
- 102000011632 Caseins Human genes 0.000 description 109
- 108010046377 Whey Proteins Proteins 0.000 description 78
- 102000007544 Whey Proteins Human genes 0.000 description 74
- 239000005862 Whey Substances 0.000 description 67
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 29
- 239000008103 glucose Substances 0.000 description 29
- 208000035475 disorder Diseases 0.000 description 28
- 235000001727 glucose Nutrition 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 23
- 241000700159 Rattus Species 0.000 description 18
- 230000037396 body weight Effects 0.000 description 18
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 235000009508 confectionery Nutrition 0.000 description 12
- 235000021119 whey protein Nutrition 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 235000019577 caloric intake Nutrition 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000014101 glucose homeostasis Effects 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 7
- 235000020825 overweight Nutrition 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 108010028463 kappa-casein glycomacropeptide Proteins 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 235000004213 low-fat Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000005905 Hydrolysed protein Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000012182 cereal bars Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000006362 insulin response pathway Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 208000018773 low birth weight Diseases 0.000 description 2
- 231100000533 low birth weight Toxicity 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 235000020166 milkshake Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000006180 nutrition needs Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XRCRJFOGPCJKPF-UHFFFAOYSA-N 2-butylbenzene-1,4-diol Chemical compound CCCCC1=CC(O)=CC=C1O XRCRJFOGPCJKPF-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- YPMOAQISONSSNL-UHFFFAOYSA-N 8-hydroxyoctyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCO YPMOAQISONSSNL-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000020218 follow-on milk formula Nutrition 0.000 description 1
- 235000019138 food restriction Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000020209 toddler milk formula Nutrition 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1524—Inert gases, noble gases, oxygen, aerosol gases; Processes for foaming
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a nutritional composition for use in, prevention and/or reducing the risk of a metabolic syndrome disorder, wherein the nutritional composition comprises casein.
- prenatal and early postnatal periods are now recognized as critical windows for early programming, with interest focused upon the size at birth (2;7;8), breast feeding and its duration; (9-13), kinetics of early growth (6;14-16), and more recently on the protein content of infant formula (17).
- the present inventors have surprisingly shown that rats which were fed a diet with casein protein as pups, experience a protective effect on insulin sensitivity when they were exposed to an adipogenic diet as adult rats. In contrast, rats which had been fed a diet with whey protein as pups were not protected when exposed to an adipogenic diet as adults. Instead, the rats which had been fed whey-based diet as pups, displayed impaired insulin sensitivity, indicated by an increased HOMA-IR.
- HOMA-IR homeostatic model assessment of insulin resistance
- HOMA-IR homeostatic model assessment of insulin resistance
- compositions comprising bovine casein proteins improves insulin sensitivity in the specific cases of low birth weight, and in normal birth weight which experience accelerated growth (catch up growth), following energy restriction.
- bovine casein proteins relative to whey
- the present inventors have surprisingly shown that the feeding of casein early in life can improve glucose tolerance in short-term and improve insulin sensitivity in long-term, later in life. This is especially apparent when subjects are challenged with adipogenic diet in adult age, later in life.
- a first aspect of the present invention relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder later in life, wherein a) the composition comprises more than 70 weight % casein based on the total protein content of the composition, and b) the composition is to be administered to the infant or young child from birth up to 36 months of age.
- the invention relates a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder later in life, wherein a) the composition comprises more than 70 weight % casein based on the total protein content of the composition, and b) the composition is to be administered to the infant or young child from birth up to 36 months of age, and wherein the total protein content of the nutritional composition is at least 0.5 g protein/100 kcal.
- Another aspect of the present invention relates to the use of casein for the preparation of a nutritional composition for use in treatment, prevention or reducing the risk of a metabolic syndrome disorder later in life in an individual, wherein: a) the composition comprises more than 70 weight % casein based on the total protein content of the composition, and b) the composition is to be administered to the infant from birth up to 36 months.
- the invention also provides a method of treating, preventing, and/or reducing the risk that an infant or child will develop a metabolic syndrome disorder later in life; in particular when challenged with adipogenic diet, said method comprising the step of administering a nutritional composition comprising more than 70 weight % casein based on the total protein content of the composition.
- FIG. 1 shows a diagram of the experimental design, including all the interventions.
- FIG. 2 shows Total energy intake during phase I (A), phase II (B) and whole study (phase I & phase II) (C). Results are expressed as med ⁇ SEMedian. * significant difference with P ⁇ 0.05; # significant difference with P ⁇ 0.01
- FIG. 3 shows Body weight during the experimental diet (Phase I) (A) and body weight throughout the study (B) Data are presented as med ⁇ SEMed. $ Significant difference between Casein 20 E % and Casein 36 E %; & significant difference between Casein 20 E % and Whey 20 E %; * significant difference between Whey 36 E % and Casein 36 E %. ° All groups are different.
- FIG. 4 shows Fat mass content as % BW. Data are represented as median ⁇ SEMedian. $ Significant difference (P ⁇ 0.05) between Casein20 E % and Casein 36 E %; ⁇ significant difference (P ⁇ 0.05) between Whey 20 E % and Whey 36 E %;*significant difference (P ⁇ 0.05) between Whey 36 E % and Casein 36 E %.
- FIG. 5 shows the results of Oral glucose tolerance test measured at the end of the experimental diet (i.e Phase I) (42 days old).
- A Baseline glycemia
- C Area under the glucose curve
- D Area under the insulin curve
- FIG. 6 shows the fasting glucose homeostasis at the end of the chow diet (ie end of Phase II:A)(165 days old).
- Fasting glycemia A
- Fasting insulinemia B
- HOMA-IR C
- Results are expressed as med ⁇ SEMedian. * significant difference with P ⁇ 0.05; # significant difference with P ⁇ 0.01.
- FIG. 7 shows Oral glucose tolerance test at the end of the study ie at the end of Phase II:B(287 days old).
- Results are expressed as med ⁇ SEMedian.
- FIG. 8 shows the HOMA-IR levels throughout the study.
- Phase I 42 days old
- Phase II chow diet
- Phase II A, 165 days old
- HFD high fat diet
- Phase ILB 287 days old
- Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 1 to 8, from 3 to 7, from 4 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
- infant means a child under the age of 12 months.
- young child means a child older than 12 months and up until 3 years of age.
- reducing the risk of means that the event is less likely to happen compared to the appropriate and usual reference (such as a general population or normal weight infants or young children).
- prevention means that the event or disorder is prevented from taking place either completely, or partially (i.e., a milder form occurs and/or occurs later).
- prevention also comprises a reduction in the severity of the event or disorder (or health condition) or a reduction in the frequency of occurrence of such events or disorders or a delaying effect on such events or disorders.
- normal weight/overweight/underweight refer to the internationally recognized tables for weight of infants, young children and children, and are in particular function of the age of the subject.
- the invention in a first aspect relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder later in life, wherein a) the composition comprises more than 70 weight % casein based on the total protein content of the composition, and b) the composition is to be administered to the infant or young child from birth up to 36 months of age.
- Casein as used in the present application refers to the family of related proteins found in mammalian milk.
- the casein may be from any suitable source or combination of sources of mammalian milk. Examples of sources include, for example, cow, goat, buffalo, sheep etc.
- sources include, for example, cow, goat, buffalo, sheep etc.
- One embodiment relates to a composition for use according to the invention wherein the casein is bovine. Bovine casein is readily available commercially.
- the nutritional composition according to the invention comprises more than 70% weight casein based on the total protein content of the composition.
- composition comprises for example at least 75 weight %, at least 80 weight %, at least 85 weight %, at least 90 weight %, at least 95 weight %, at least 99 weight %, about 100 weight % casein based on the total protein content of the composition.
- the nutritional composition comprises at least 85 weight % casein based on the total protein content of the composition, such as at least 90%, for example at least 95 weight %, at least 99 weight %, or for example 100 weight % of casein based on the total protein content of the composition.
- 100% of the protein present in a nutritional composition for use according to the invention is casein.
- the total protein content of nutritional composition according to the invention may be for example at least 5 g/l, for example at least 6 g/l, for example at least 7 g/l, such as at least 8 g/l, for example at least 9 g/l, such as at least 10 g/l, at least 11 g/l, for example at least 12 g/l, such as at least 15 g/l, or for example 18 g/l; or may be for example about 9 or about 10 g/l.
- the total protein content of nutritional composition for use according to the invention may be from 3 g/l to 33 g/l ready to consume composition, such as from 3 g/l to 25 g/l, for example 5 to 20 g/l, for example 8 to 20 g/l.
- the total protein content of a nutritional composition according to the invention may be required by a food authority to meet certain specifications regarding amount of protein.
- the total protein content may be for example from 3 g/l to 15 g/l of ready to consume formula, such as 5 to 15 g/l, such as 3 to 10 g/l.
- the total protein content may also be expressed as g protein per kcal of nutritional composition.
- the total amount of protein may be for example at most 5 g/100 kcal of ready to consume formula, for example from 1 to 4 g/100 kcal, such as from 1 to 3.5 g/100 kcal, such as from 1.5 to 2.5 g/100 kcal, such as from 1.6 to 2.2 g/100 kcal.
- One specific embodiment relates to a nutritional composition for use according to the invention, wherein the total protein content is 1.8 g/100 kcal of ready to consume formula.
- a further specific embodiment of the present invention relates to an infant formula wherein the total protein content is from 1.6 to 2.2 g/100 kcal, such as 1.8 g/100 kcal, and wherein more than 70% of the total protein content is from casein
- a still further embodiment of the embodiment of the present invention relates to an infant formula wherein the casein content is at least 0.45 g casein/100 kcal of ready to consume formula.
- Nutritional compositions of the invention which are intended for young children may have the same protein content as nutritional compositions which are intended for infants, or may comprise higher or lower levels of protein.
- a nutritional composition for young children may comprise lower total protein content, for example 0.5 to 5 g/100 kcal, such as from 0.5 to 3.5 g/100 kcal, such as from 1 to 2.5 g/100 kcal; or for example from 0.5 to 1.5 g/100 kcal total protein content.
- the proteins may be intact or hydrolysed or a mixture of intact and hydrolysed proteins.
- the hydrolysed proteins can be fully hydrolysed or partially hydrolysed.
- the nutritional composition of the invention comprises more than 70% casein based on the total protein content of the composition
- the remainder of the protein content may comprise one or more protein suitable for consumption by infants or young children provided that the minimum requirements for essential amino acid content are met.
- the total protein content of the composition may consist of a mixture of casein and whey proteins, such as a mix of bovine casein and bovine whey proteins. If whey proteins are to be used, they may be acid whey or sweet whey or mixtures thereof and may include alpha-lactalbumin and beta-lactoglobulin in whatever proportions are desired.
- the protein source may additionally be supplemented with free amino acids if this is necessary to meet the minimum requirements for essential amino acid content. These requirements are published for example in EC Directive 2006/14 I/EC.
- the total protein content of the composition may consist of casein and one or more non-dairy proteins, for example selected from the group consisting of meat, fish, egg, and/or vegetarian protein sources such as pea, rice and the like.
- the ratio of casein to the remainder of the protein content may be from 70:30 to 100:0 (casein:remainder of protein).
- Examples of ratios are 70:30, 80:20, 85:15, 90:10, 95:5, 100:0 (casein:remainder of protein).
- the protein source may be a mixture of casein and whey proteins.
- the whey protein may be a whey protein isolate, acid whey, sweet whey or sweet whey from which the caseino-glycomacropeptide has been removed (modified sweet whey).
- the whey protein is modified sweet whey.
- Sweet whey is a readily available by-product of cheese making and is frequently used in the manufacture of nutritional compositions based on cows' milk.
- sweet whey includes a component which is undesirably rich in threonine and poor in tryptophan called caseino-glycomacropeptide (CGMP). Removal of the CGMP from sweet whey results in a protein with a threonine content closer to that of human milk.
- a process for removing CGMP from sweet whey is described in EP 880902.
- modified sweet whey is used as the whey protein in a mixture of 60% whey and 40% casein
- the protein source may be supplemented by free tryptophan, isoleucine, histidine and phenylalanine in amounts of up to 0.34% for tryptophan, 0.92% for isoleucine, 0.19% for histidine and 2.2% for phenylalanine (in each case as a percentage by weight of total protein content).
- the protein source may be supplemented by free tryptophan, leucine, histidine and phenylalanine in amounts of up to 0.5% for tryptophan, 0.37% for leucine, 0.3% for histidine and 2.5% for phenylalanine (in each case as a percentage by weight of total protein content).
- the protein source may also be supplemented by amino acids rich in sulphur such as cysteine and methionine if desired.
- the inventors have shown that adult rats which were fed a diet where casein was predominant protein source as pups, display an improved HOMA-IR index when challenged with an adipogenic diet as adults, as compared to rats which were fed a diet where whey was predominant source of protein as pups.
- the invention relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder later in life, wherein a) the composition comprises more than 70 weight % casein based on the total protein content of the composition, and b) the composition is to be administered to the infant or young child from birth up to 36 months of age.
- metabolic syndrome disorder refers to one or more disorders associated with Metabolic Syndrome. These disorders are typically a result of a dysregulation of the glucose homeostasis. Examples of such disorders include diabetes such as diabetes mellitus, impaired glucose tolerance, impaired fasting glucose, insulin resistance, hypertension, dyslipidemia, overweight, obesity (particularly central obesity) and microalbuminuria.
- the invention relates in one embodiment to the composition for use according to the invention wherein the disorder is selected from the group consisting of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose, insulin resistance, hypertension, dyslipidemia, overweight, obesity (particularly central obesity) and microalbuminuria.
- the invention relates to the composition for use according to the invention, wherein the use is to improve insulin sensitivity, to promote normal weight and/or to prevent overweight later in life.
- the present invention relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder later in life.
- the term “later in life” in the context of the present invention refers to the period of time after childhood, that is after 12 years of age.
- the metabolic syndrome disorder appears after 12 years of age, or for example after 15 years of age, such as after 18 years of age, such as after 25 years of age, after 30 years of age, after 35 years of age.
- the experimental data shows that when adult rats where challenged with a high fat (i.e., adipogenic) diet, adults who had been fed casein 36 E % diet as pups displayed a lower HOMO-IR (indicative of a better insulin sensitivity), as compared to those adults which had been fed a whey 36 E % diet as pups.
- a high fat diet i.e., adipogenic
- a further embodiment of the invention relates to a composition for use according to the invention wherein the use is in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder appearing later in life when exposed to an adipogenic diet.
- adipogenic diet in the context of the present invention relates to a diet which will lead to increased fat mass of the individual. Generally speaking, an excess of energy intake will lead to increased fat mass, therefore one example of a adipogenic diet is a diet where the caloric intake exceeds the individual's required caloric need. Other examples of an adipogenic diet include the typical Western diet, also known as the western pattern diet or Standard American Diet. Another example of an adipogenic diet is where the diet is characterized by a fat content that exceeds the dietary recommendation of 30% of the energy from fat, high sugar diet and/or that wherein the caloric intake exceeds the individual's required caloric need.
- the composition for use according to the invention when administered early in life (for example to an infant or young child), will protect that individual if and when said individual later in life (for example as an adult, or for example after 18, after 20, after 25, after 30 years of age) eats a diet which is adipogenic.
- protect it is meant that glucose homeostasis and/or insulin sensitivity will not be impaired, or will be not be impaired to same extent.
- the use of the composition of the invention at the time of administration, modulates the metabolic pathways. Such modulation enables a specific metabolic reaction when the subject is exposed to an adipogenic diet later in life.
- Such modulation may affect all subjects exposed to the composition of the invention and may not be dependent of whether the subjects have expressed particular metabolic signals of “stressed immediate nutritional needs”. For example such modulation may differ from the immediate modulation in subjects having already generated metabolic signals at time of administration of the composition (such as subjects undergoing a catch-up growth or low birth weight infants; i.e infant in stressed immediate nutritional needs).
- stressed nutritional signals are present at time of administration, specific metabolic pathways are activated in order to respond to the stress signals.
- some other metabolic pathways are activated and induce the long term effect, especially when exposed to a adipogenic diet later in life.
- the present invention relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder, wherein a) the composition comprises more than 70 weight % casein based on the total protein content of the composition, and b) the composition is to be administered to a infant or young child from birth up to 36 months of age.
- the invention relates to the composition for use according to the invention, wherein the use is to improve insulin sensitivity, to promote normal weight and/or to prevent overweight.
- composition for use according to the invention is to be administered to an infant or young child.
- the infant or young child is for example born to a mother who herself suffered or suffers from one or more metabolic syndrome disorders, such as one or more selected from the group consisting of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose, insulin resistance, hypertension, dyslipidemia, overweight, obesity (particularly central obesity) and microalbuminuria, or from gestational diabetes.
- one or more metabolic syndrome disorders such as one or more selected from the group consisting of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose, insulin resistance, hypertension, dyslipidemia, overweight, obesity (particularly central obesity) and microalbuminuria, or from gestational diabetes.
- the infant or young child is deemed to be at risk for one or more metabolic syndrome disorders, for example due to a familial risk, such as family history.
- the composition for use is to be administered to an infant or young child, regardless of birth weight.
- composition for use according to the invention is to be administered to an infant or young child whose birth weight was normal. In another embodiment the birth weight of the infant or young child was above normal.
- the present invention relates to a composition for use according to the invention, wherein the composition is to be administered to an infant or young child who has not undergone a period of catch-up growth following a period of growth restriction.
- the present invention relates to a composition for use according to the invention, wherein the composition is to be administered to infant or young child who was born with normal birth weight and with a non restricted food intake and normal growth during infancy and/or young age.
- the invention relates to the surprising finding that administration of casein based nutritional compositions to an infant or young child can protect from metabolic syndrome disorders later in life.
- composition for use according to the invention is to be administered to the infant or young child in a time period from birth to 36 months.
- the administration falls in a time period from birth to 36 months, or 24 months, such as to 18 months, for example to 12 months.
- composition for use according to the invention is administered to an infant or young child during the weaning period.
- the weaning period refers to the period in an infant's or young child's life where they are transitioned from milk feeding (such as breast milk feeding) to solid foods. This period depends on the individual infant or young child, but typically falls within the range from 4 months to 18 months of age, such as from 6 to 18 months.
- the composition for use according to the invention is administered to an infant or young child during the weaning period and not before (i.e. starting at the weaning period). In one embodiment the administration starts shortly before the weaning period (for example 1 month before the start of the weaning).
- administration may be for example intermittent during said period, or for example on average once daily over said the period, or for example once every other day over said period, or for example at least once daily during said period.
- the administration of the composition is for a shorter duration of time falling within the time period mentioned above, for example on average once daily for a duration of at least six weeks in said time period; such as for example on average once daily for 3, 6, 8, 9 months during said time period.
- the administration may be for example on average once every other day for a period of at least six weeks in the period from birth to 36 months, such as for example on average once every other day for a period of 3, 6, 8, or 9 months during said time period.
- the invention relates to a use according to the invention, wherein a composition is administered at least once a day for at least 1 month.
- a medical food is a special class of nutritional composition designed to provide dietary management of certain conditions.
- the medical food meets certain criteria as set out by and regulated under the Orphan Drug Act of 1983 in Section 5 [360ee](b)(2)(D).
- the medical food may be presented in any suitable format, as discussed below.
- one embodiment of the invention relates to a nutritional composition according to the invention wherein the nutritional composition is a medical food.
- the nutritional composition according to the invention may be in any suitable format.
- the format of the nutritional composition for use according to the invention may be tailored to suit the age of the infant or young child to whom it is administered.
- Examples of nutritional composition formats suitable for infants include an infant formula, a follow-on formula, a growing up milk, a human milk fortifier.
- the infant formula may be for example a nutritionally complete formula.
- Examples of formats suitable for infants and/or young children include ready-to-drink compositions, liquid comestibles, milk drinks, milk-shakes, milk-biscuits, yoghurts, soups, desserts, puddings, bars such as cereal bars, porridges, beverages and baby foods.
- the format of the nutritional composition is a dairy-based format, such as for example milk and milk drinks, milk-shakes, milk biscuits, yoghurts and other cultured milk products, ice creams and cheeses.
- Further nutritional composition formats include products comprising dairy products, for example, baked products, dairy products, desserts, confectionery products, cereal bars, breakfast cereals.
- the nutritional composition for use according to the invention is an infant formula.
- infant formula for use according to the invention may comprise, besides the protein source as discussed previously above, also a carbohydrate source and a lipid source.
- carbohydrate source conventionally found in infant formulas such as lactose, saccharose, maltodextrin, starch and mixtures thereof may be used although the preferred source of carbohydrates is lactose.
- carbohydrate content of the infant formula is between 9 and 14 g/100 kcal.
- An infant formula for use according to the present invention may further contain a source of lipids.
- the lipid source may be any lipid or fat which is suitable for use in infant formulas. Suitable fat sources include palm olein, high oleic sunflower oil, linseed oil and high oleic safflower oil although a combination of linseed oil and high oleic safflower oil is preferred. Small amounts of oils containing high quantities of preformed arachidonic acid (ARA) and docosahexaenoic acid (DHA) such as fish oils or microbial oils may be included. In total, the lipid content may be between 4.4 and 6 g/100 kcal.
- ARA arachidonic acid
- DHA docosahexaenoic acid
- the ratio of linoleic acid (C18:2n-6): [alpha]-linolenic acid (C18:3n-3) in the lipid source is less than 7:1, more preferably between 7:1 and 5:1.
- the infant formula may also contain all vitamins and minerals understood to be essential in the daily diet and in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the infant formula include vitamin A, vitamin B 1, vitamin B2, vitamin B6, vitamin B 12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form.
- infant formula may contain emulsifiers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like.
- the infant formula may optionally contain other substances which may have a beneficial effect such as probiotic lactic acid bacteria, prebiotic oligosaccharides, lactoferrin, nucleotides, nucleosides, and the like.
- the formula may be prepared in any suitable manner. For example, it may be prepared by blending together the protein, the carbohydrate source, and the fat source in appropriate proportions. If used, the emulsifiers may be included at this point. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture. The temperature of the water is conveniently about 50° C. to about 80° C. to aid dispersal of the ingredients. Commercially available liquefiers may be used to form the liquid mixture. The liquid mixture is then homogenized; for example in two stages.
- the liquid mixture may then be thermally treated to reduce bacterial loads, by rapidly heating the liquid mixture to a temperature in the range of about 80° C. to about 150° C. for about 5 seconds to about 5 minutes, for example.
- This may be carried out by steam injection, autoclave or by heat exchanger; for example a plate heat exchanger.
- the liquid mixture may be cooled to about 60° C. or about 85° C.; for example by flash cooling.
- the liquid mixture may then be again homogenized; for example in two stages at about 10 MPa to about 30 MPa in the first stage and about 2 MPa to about 10 MPa in the second stage.
- the homogenized mixture may then be further cooled to add any heat sensitive components; such as vitamins and minerals.
- the pH and solids content of the homogenized mixture are conveniently adjusted at this point.
- the homogenized mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
- the powder should have a moisture content of less than about 5% by weight. If a liquid product is preferred, the homogenized mixture may be sterilized then aseptically filled into suitable containers or may be first filled into the containers and then retorted.
- the invention in a further aspect relates to a method of treatment, prevention and/or reducing the risk of a metabolic syndrome disorder, in particular insulin resistance, said method comprising administering to an infant or young child a nutritional composition according to the invention.
- compositions for use according to the invention are herein described by different parameters, such as the ingredients, nutritional composition formats, uses, target groups etc. It should be noted that embodiments and features described in the context of one of the parameters of the composition for use according to the invention, may also be combined with other embodiments and features described in the context of another parameter, unless expressly stated otherwise.
- dams and their pups bearing at least 8 pups with minimum 3-4 males per litter were included in the study.
- the number of pups in each litter was limited to 8, with preference to male pups.
- All dams were fed ad-libitum with a rat chow diet (Kliba 3437) during the lactation period.
- the pups remained with their mother until age of 16 days (2 days after eye opening). During this period, they were allowed to suckle ad-libitum from dams.
- Pups were separated from dams and the same number of male pups from each litter (sibling) were randomly allocated into one of the following four study groups based on their body weight.
- Pups were fed with one of the following experimental diet different in type of protein (casein or whey) or level of protein (20 E % or 36 E % protein). from age of 16 d until 45 d of age.
- the diets were isonitrogenous at same level of protein and isoenergetic in all groups.
- the extra protein in high protein groups (36 E % protein) was exchanged with carbohydrate (corn starch).
- the composition of experimental diet is shown in in Table 2.
- phase I Six pups per group were euthanized at the end of phase I (d42-45) by decapitation as described in below.
- Animals of the same group were first caged collectively (5/cage) for few days (D16 to D20-21) and then separated and caged individually until the end of the study. They were kept in the same room at 23 ⁇ 3° C. with 55% relative humidity and a 12 h light/dark cycle during the study.
- Plasma insulin was measured by an ELISA method using kits from Crystal Chem. Inc (IL, USA). Plasma triglycerides (TG), free fatty acids, glucose and cholesterol were measured at euthanasia using automated chemistry analyzer (COBAS C111 Roche) with the following kits: triglycerides enzymatic kit (Roche Diagnostics, Rotnch, CH), free fatty acids enzymatic kit (Wako Chemicals GmbH, Neuss, De), cholesterol enzymatic kit (Roche Diagnostics, Rotnch, CH), IGF-1 (IDS, LTD, UK).
- pancreas was homogenized with an acid-ethanol (solution v/v: 75% ethanol, 1.5% of 37% HCl and 23.5% distilled water) and incubated at ⁇ 20° C. overnight.
- the insulin content in the supernatant was measured by an ELISA method using kits from Crystal Chem. Inc (IL, USA).
- Phase I refers to the phase of the diet where the experimental diet was fed to the pups.
- Phase II all pups received the same diets.
- Phase II:A the pups were fed a normal commercial diet.
- Phase II: B the pups were challenged with a High Fat Diet.
- FIG. 2 shows the total energy intake
- Casein 20 E % had a significantly higher energy intake than both Whey 20 E % and Casein 36 E % during Phase I (kcal: 1088 ⁇ 12; 982.4 ⁇ 25; 932 ⁇ 12, respectively, P ⁇ 0.0001) as well as phase II (when all groups were fed with the same diet), and hence whole study period (phase I+phase II) (p ⁇ 0.05).
- Whey 20 E % and Whey 36 E % had similar energy intake during both study phases and hence during whole study period (p>0.05 in all cases).
- Casein 36 E % and Whey 36 E % had similar energy intake during phase I. Although Whey 36 E % had higher energy intake than Casein 36 E % during phase II, this difference was only statistically significant during the high fat challenge period (p ⁇ 0.05) and not entire phase II or whole study period (p>0.05).
- FIGS. 3 and 4 illustrate the body weight and body weight gain.
- Casein groups at both levels of protein (20 E % and 36 E %) had a greater weight gain (p ⁇ 0.0001) than corresponding Whey-fed groups, resulting in a higher body weight (p ⁇ 0.0001) (See FIG. 3A ).
- Casein-fed rats had greater weight gain (Casein 20 E %: 156 ⁇ 2.4 g; Casein 36E %: 144 ⁇ 1.6 g; p ⁇ 0.02) resulting in higher body weight at d42 (Casein 20 E %: 196 ⁇ 2.3 g; Casein 36 E %: 184 ⁇ 2.6 g; p ⁇ 0.02).
- Casein 20 E % remained heavier than Casein 36 E % while the body weight gain of all 4 groups were similar during the low fat chow diet period. However, during high fat challenge period, Casein 20 E % gained more weight than both of Casein 36 E % and Whey 20 E % (10% and 8% higher, p ⁇ 0.01 and p ⁇ 0.05 respectively, FIG. 3B ). This was the same for entire duration of study.
- Table 3 summarized the changes in body composition.
- Glucose homeostasis was assessed at different time courses during the study either by performing an oral glucose tolerance test or by measuring fasting value (described above in Materials and Methods).
- Phase I The experimental diet of Phase I had an effect on the glucose tolerance, as is illustrated in FIG. 8 .
- whey-fed groups presented both a higher AUC glucose (p ⁇ 0.05) and higher Cmax glucose values (p ⁇ 0.05) relative to casein-fed groups, suggesting a lower glucose tolerance in response to whey diet.
- Casein 36 E % had a higher fasting glycemia than Casein 20 E % (respectively; 6.7 ⁇ 0.14 and 6.1 ⁇ 0.15 mmol/l, p ⁇ 0.05).
- Casein 20 E % had lower baseline glycemia than Casein 36 E % (fasting blood glucose measured prior to glucose challenge). Both casein fed groups lead to better Glucose tolerance immediately at the end of the Phase I.
- HOMA-IR insulin resistance
- An oral glucose tolerance test was also performed at age of 287 days, after 5 weeks on high fat diet, and results are represented in FIG. 7 .
- Whey 36 E % had both a significant higher baseline glycemia and insulinemia than Casein 36 E % (p ⁇ 0.05) and also higher insulinemia than Whey 20 E % (p ⁇ 0.05). After a glucose challenge, the insulin response curve showed that Casein 20 E % had a higher Cmax insulin value than Casein 36 E % (p ⁇ 0.01) and also a higher AUC insulin (p ⁇ 0.05).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pediatric Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
TABLE 1 |
Study design |
Gestation | Suckling | ||||
period | period | Phase I | Phase | ||
Diet | Kilba | ||||
3437 | | Experimental | D46-D255: | ||
| Kilba | 3437 | |||
D256-D269 | |||||
Kilba 2126 | |||||
Food intake + | 1/week | 1/ | 5/week | Once a week | |
spillage | Pair-feeding | ||||
measurement | if required | ||||
Body weight | 1/week | None | 3/week | Once a week | |
measurement | At D16 | ||||
NMR | D17-18 | D105-106 | |||
D37-389 | D162-163 | ||||
D224-225 | |||||
D252-523 | |||||
D282-283 | |||||
GTT | D42 to | D164-165: | |||
D45 | fasting | ||||
(n = 20/grp) | glycemia | ||||
insulinemia | |||||
(n = 22) | |||||
D287-290: | |||||
GTT | |||||
(n = 15/grp) | |||||
| D49-50 | D297 to 298 | |||
(n = 6 | (n = 7 | ||||
rats per | rats per | ||||
group) | group) | ||||
D = days |
Coupling Conditions and Gestation Period
-
- a) Casein 20 E % group (Casein 20 E %)
- b) Whey 20 E % group (Whey 20 E %)
- c) Casein 36 E % group (Casein 36 E %)
- d) Whey 36 E % group (Whey 36 E %)
TABLE 2 |
|
20 | 20 | 36 | 36 Whey | |
Products | diet | diet | diet | diet |
Corn starch | 53 | 53 | 37 | 37 |
| 20 | — | 36 | — |
Whey | — | 20 | — | 36 |
| 10 | 10 | 10 | 10 |
Soybean oil | 7 | 7 | 7 | 7 |
| 5 | 5 | 5 | 5 |
Mineral mix | 3.5 | 3.5 | 3.5 | 3.5 |
AIN93G | ||||
Vitamin mix | 1.0 | 1.0 | 1.0 | 1.0 |
AIN93 | ||||
L-cysteine | 0.3 | 0.3 | ||
Bitartr. choline | 0.25 | 0.25 | 0.25 | 0.25 |
Tert- | 0.014 | 0.014 | 0.014 | 0.014 |
butylhydroquinone | ||||
Total (wet weight) | 100 | 100 | 100 | 100 |
Kcal/100 g diet | 362.0 | 362.0 | 368.2 | 368.2 |
(calculated on | ||||
analysed humidity | ||||
basis) | ||||
% Dry Wt of | 93.1 | 92.8 | 94.1 | 94.0 |
powder (based on | ||||
ingredient | ||||
humidity basis) | ||||
% Dry Wt final | 90.8 | 90.7 | 88.5 | 88.4 |
pellet (analysis) | ||||
Kcal/100 g | 353.02 | 353.77 | 346.28 | 346.26 |
powder (final | ||||
pellet) | ||||
% Energy | ||||
Protein (basis on | 21.2 | 21.7 | 35.3 | 36.0 |
nunspeed nitrogen | ||||
results * 6.38) | ||||
Protein (from | 21.4 | 21.4 | 37.6 | 37.6 |
ingredient based | ||||
on humidity | ||||
results) | ||||
CHO | 61.2 | 61.2 | 45.3 | 45.3 |
Fat | 17.4 | 17.4 | 17.1 | 17.1 |
% Total energy | 99.8 | 100.3 | 97.7 | 98.4 |
(protein from | ||||
nunsped results) | ||||
% Total enery | 100.0 | 100.0 | 100.0 | 100.0 |
(protein from | ||||
ingredient based | ||||
on humidity | ||||
results | ||||
Whey: prolacta 90 (lactalis) | ||||
Casein: from animal house (protein = dry weight) |
Post Weaning Period (or Phase II)
-
- Body weight of pups was recorded three times per week and food intake was measured during all working days from d16 to d45 (phase I). Then, body weight and food intake were measured once per week until the end of the study (phase II).
- Body composition was measured by nuclear magnetic resonance (NMR) at 17, 37, 104, 162, 224 and 252d.
- After 6 hr fast, blood samples were obtained from puncture of the tail at day 164±1, glucose was measured with a glucometer (Ascensia Elite XL, Dublin, Ireland) and blood was centrifuged for plasma recovery.
- An oral glucose tolerance test (OGTT) was performed after 6 hr of day food deprivation (from 7.30 am to 13.30 pm) in 20 offspring per group at age of 42±3 and 287±3 days.
RT-PCR
-
- For the body weight and body weight gain (longitudinal data), a mixed model has been used in each phase of the study (phase I experimental diet; phase II commercial chow diet; phase II high fat diet). These linear mixed models use group, day, squared-day and the pair-wise interactions of group and day variables as fixed effects and a random day and squared-day effect.
TABLE 3 |
Fat gain during different study period |
Casein | | Casein | Whey | ||||||
20 | 20 | | | 20 | 20 | | | ||
During low fat chow diet (46-225 d) | During high fat diet (226-311 d) |
Fat | 108 ± 9 | 90 ± 9 | 90 ± 5$ | 99 ± 8 | 106 ± 7 | 87 ± 9 | 71 ± 5$ | 85 ± 6 |
gain | ||||||||
(g) |
Total phase II | Total Study |
Fat | 221 ± 15 | 171 ± 18 | 156 ± 7$ | 184 ± 12 | 237 ± 14 | 184 ± 19 | 166 ± 7$ | 191 ± 11 |
gain | ||||||||
(g) | ||||||||
% fat | 19 ± 1.3 | 15.5 ± 1.7 | 14.6 ± 0.8 | 15.9 ± 1.0 | 16 ± 1.5 | 11 ± 1.3 | 12 ± 1.09$ | 13 ± 0.9 |
change | ||||||||
Fat/lean | 0.38 ± 0.03$ | 0.28 ± 0.03 | 0.27 ± 0.01 | 0.32 ± 0.02 | 0.35 ± 0.03 | 0.26 ± 0.02 | 0.24 ± 0.02$ | 0.30 ± 0.02 |
ratio | ||||||||
Glucose Homeostasis after Phase I
- 1. Barker D J et al Horm Res 42, 223-230. 1994.
- 2. Lucas A. CIBA Foundation Symposium 156. Whiley, Chichester, UK. 38-55. 1991.
- 3. Lucas A et al. BMJ 319, 245-249. 2012.
- 4. Barker et Lancet, 938-941. 1993.
- 5. Lanigan J et al Proc Nutr Soc. 68, 422-429. 2009.
- 6. Hales C N et al. BMJ 303, 1019-1022. 1991.
- 7. McCance. BMJ 308, 942-945. 1994.
- 8. Okosun et al, Int J Obes. Related Matab Disord 24, 479-484. 2000.
- 9. Perrie F. O'Tierney et al. The journal of Nutrition 139, 422-425. 2009.
- 10. Owen C G et al. Pediatrics 115, 1367-1377. 2005.
- 11. Harder The et al. Am J Epidemiol. 162, 397-403. 2005.
- 12. K B Michels et al. International Journal of Obesity 31, 1078-1085. 2007.
- 13. Kramer M S et al. Am J Clin Nutr 86, 1717-1721. 2007.
- 14. Law C M et al. J
Epidemiol Community Health 46, 184-188. 1992. - 15. Eriksson J G et al. Diabetes Care 26, 3006-3010. 2003.
- 16. Forsen T J et al. Ann Med. 2004; 36:389-92. Ann Med. 2004.
- 17. Berthold et al. The American Journal of Clinical Nutrition 89, 1836-1845. 2009.
Claims (15)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13195014.9 | 2013-11-29 | ||
EP13195014 | 2013-11-29 | ||
EP13195014 | 2013-11-29 | ||
PCT/EP2014/075831 WO2015078974A1 (en) | 2013-11-29 | 2014-11-27 | Infant nutrition for improvement in insulin sensitivity later in life |
Publications (2)
Publication Number | Publication Date |
---|---|
US20160296585A1 US20160296585A1 (en) | 2016-10-13 |
US10821150B2 true US10821150B2 (en) | 2020-11-03 |
Family
ID=49679400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/100,427 Active US10821150B2 (en) | 2013-11-29 | 2014-11-27 | Infant nutrition for improvement in insulin sensitivity later in life |
Country Status (8)
Country | Link |
---|---|
US (1) | US10821150B2 (en) |
EP (1) | EP3082472A1 (en) |
CN (1) | CN105578904A (en) |
AU (1) | AU2014356485A1 (en) |
MX (1) | MX2016006882A (en) |
PH (1) | PH12016500950A1 (en) |
RU (1) | RU2694827C1 (en) |
WO (1) | WO2015078974A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2862774T3 (en) * | 2016-04-11 | 2021-10-07 | Nestle Sa | Infant nutrition that provides metabolic benefits |
WO2020108915A1 (en) * | 2018-11-30 | 2020-06-04 | Societe Des Produits Nestle S.A. | Infant nutritional composition for use in the enhancement of pancreatic maturation and insulin biosynthesis |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083164A2 (en) | 2001-04-10 | 2002-10-24 | Societe Des Produits Nestle S.A. | Method and composition for prophylaxis of diabetes |
WO2008054192A1 (en) | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
EP1932437A1 (en) * | 2006-12-15 | 2008-06-18 | Nestec S.A. | Infant formula |
WO2010027258A1 (en) | 2008-09-02 | 2010-03-11 | N.V. Nutricia | Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids |
WO2010112429A1 (en) | 2009-04-01 | 2010-10-07 | Nestec S.A. | Reduction of risk of obesity |
WO2010112430A1 (en) | 2009-04-03 | 2010-10-07 | Nestec S.A. | Improvement in promotion of healthy catch-up growth |
WO2010119088A2 (en) | 2009-04-15 | 2010-10-21 | Bodo Melnik | Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity |
EP2583562A1 (en) | 2011-10-21 | 2013-04-24 | Nestec S.A. | Use of whey protein micelles for infants at risk of obesity or diabetes |
WO2013109367A1 (en) | 2011-12-27 | 2013-07-25 | Abbott Laboratories | Reduced calorie infant formulas containing specific whey to casein ratios |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2011506A1 (en) * | 2007-07-05 | 2009-01-07 | Nestec S.A. | Supplementation of maternal diet |
-
2014
- 2014-11-27 RU RU2016125907A patent/RU2694827C1/en active
- 2014-11-27 CN CN201480052640.5A patent/CN105578904A/en active Pending
- 2014-11-27 MX MX2016006882A patent/MX2016006882A/en unknown
- 2014-11-27 US US15/100,427 patent/US10821150B2/en active Active
- 2014-11-27 AU AU2014356485A patent/AU2014356485A1/en not_active Abandoned
- 2014-11-27 EP EP14803141.2A patent/EP3082472A1/en not_active Withdrawn
- 2014-11-27 WO PCT/EP2014/075831 patent/WO2015078974A1/en active Application Filing
-
2016
- 2016-05-23 PH PH12016500950A patent/PH12016500950A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083164A2 (en) | 2001-04-10 | 2002-10-24 | Societe Des Produits Nestle S.A. | Method and composition for prophylaxis of diabetes |
WO2008054192A1 (en) | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
EP1932437A1 (en) * | 2006-12-15 | 2008-06-18 | Nestec S.A. | Infant formula |
WO2010027258A1 (en) | 2008-09-02 | 2010-03-11 | N.V. Nutricia | Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids |
WO2010112429A1 (en) | 2009-04-01 | 2010-10-07 | Nestec S.A. | Reduction of risk of obesity |
WO2010112430A1 (en) | 2009-04-03 | 2010-10-07 | Nestec S.A. | Improvement in promotion of healthy catch-up growth |
WO2010119088A2 (en) | 2009-04-15 | 2010-10-21 | Bodo Melnik | Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity |
EP2583562A1 (en) | 2011-10-21 | 2013-04-24 | Nestec S.A. | Use of whey protein micelles for infants at risk of obesity or diabetes |
WO2013109367A1 (en) | 2011-12-27 | 2013-07-25 | Abbott Laboratories | Reduced calorie infant formulas containing specific whey to casein ratios |
Non-Patent Citations (16)
Title |
---|
Australian Office Action for corresponding Australian Application No. 2014356452, dated Oct. 3, 2018; (5 pages). |
Centers for Disease Control and Prevention (<https://www.cdc.gov/nutrition/infantandtoddlernutrition/formula-feeding/how-much-how-often.html> May 7, 2018). * |
COLEMAN D L, KUZAVA J E, LEITER E H: "EFFECT OF DIET ON INCIDENCE OF DIABETES IN NONBESE DIABETIC MICE", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 39, no. 04, 1 January 1990 (1990-01-01), US, pages 432 - 436, XP001002589, ISSN: 0149-5992 |
Coleman et al. "Effect of Diet on Incidence of Diabetes in Nonobese Diabetic Mice" Diabetes, 1990, vol. 39, pp. 432-436, XP001002589. |
Deglaire et al. ("Hydrolyzed dietary casein as compared with the intact protein reduces postprandial peripheral, but not whole-body, uptake of nitrogen in humans"; Ann J Clin Nutr 2009:90:1011-22). * |
Enteral nutrition formulary guide (<https://kr.ihc.com/ext/Dcmnt?ncid=520448890> Nov. 25, 2008). * |
Fairweather et al. "Type 1 diabetes: virus infection or autoimmune disease?" Nature Immunology, Apr. 2002, vol. 3, No. 4, pp. 338-340. |
Gillies et al. (BMJ, doi:10.1136/bmj.39063.689375.55, published Jan. 19, 2007). * |
Koletzko et al. ("Lower protein infant formula is associated with lower weight up to age 2 y: a randomized clinical trial" Am J Clin Nutr 2009:89:1836-45). * |
MayoClinic—Diabetes risk factors, copyright 1998-2017—accessed Aug. 3, 2017. * |
Obesity Prevention Source (<https://www.hsph.harvard.edu/obesity-prevention-source/obesity-causes/prenatal-postnatal-obesity/>Mar. 18, 2011). * |
Paronen et al., "Effect of Cow's Milk Exposure and Maternal Type 1 Diabetes on Cellular and Humoral Immunization to Dietary Insulin in Infants at Genetic Risk for Type 1 Diabetes", vol. 49, Issue No. 10, Oct. 2000, pp. 1657-1665. |
Stengel et al. "High-protein diet selectively reduces fat mass and improves glucose tolerance in Western-type diet-induced obese rats" Am J Physiol Regul Integr Comp Physiol, 2013, vol. 305, pp. R582-R591. |
Virginia WIC eligible formulas (<http://www.vdh.virginia.gov/content/uploads/sites/43/2017/02/Formulary.pdf>2017). * |
Virtanen et al. "Cow's Milk Consumption, Disease-Associated Autoantibodies and Type 1 Diabetes Mellitus: a Follow-up Study in Siblings of Diabetic Children" Diabetic Medicine, 1998, vol. 15, pp. 730-738. |
Web MD—Metformin oral—copyright 1998-2017, accessed Aug. 3, 2017. * |
Also Published As
Publication number | Publication date |
---|---|
EP3082472A1 (en) | 2016-10-26 |
MX2016006882A (en) | 2016-08-17 |
CN105578904A (en) | 2016-05-11 |
PH12016500950A1 (en) | 2016-06-27 |
RU2694827C1 (en) | 2019-07-17 |
US20160296585A1 (en) | 2016-10-13 |
WO2015078974A1 (en) | 2015-06-04 |
AU2014356485A1 (en) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lorenzen et al. | Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet | |
Gaby | Adverse effects of dietary fructose | |
Dugan et al. | Effects of dairy on metabolic syndrome parameters: a review | |
Wolfe et al. | Replacement of carbohydrate by protein in conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy normolipidemic subjects | |
Melnik et al. | Milk consumption during pregnancy increases birth weight, a risk factor for the development of diseases of civilization | |
US8846612B2 (en) | Promotion of healthy catch-up growth | |
JP6420156B2 (en) | Use of casein composition | |
JP2022533036A (en) | Compositions and methods for treating or preventing metabolic fatigue using the compound oleuropein or its metabolites. | |
US20110178008A1 (en) | Compositions for Enhancing the Production of PPAR and/or PPAR-Associated Factors | |
RU2559646C2 (en) | Adiposity risk reduction | |
WO2012097064A1 (en) | Nutritional compositions and methods for controlling blood glucose | |
WO2012097061A1 (en) | Nutritional compositions and methods for improving skeletal muscle protein metabolism | |
US20140127351A1 (en) | Nutritional supplements including meal replacements and related methods | |
US10821150B2 (en) | Infant nutrition for improvement in insulin sensitivity later in life | |
JP6177310B2 (en) | Promotion of infant growth | |
JP2022535687A (en) | Use of whey protein micelles to control postprandial glycemic response | |
US11388922B2 (en) | Infant nutrition delivering metabolic benefits | |
Shahkhalili et al. | The Fat: Carbohydrate Energy Ratio of the Weaning Diet Programs Later Susceptibility to Obesity in Male Sprague Dawley Rats3 | |
Jahan‐mihan et al. | The effect of characteristics of proteins fed during gestation and lactation on development of metabolic syndrome in dams and male offspring of Wistar rats | |
WO2022258694A1 (en) | Probiotic and uses thereof | |
Šebeková et al. | Advanced glycation end products in infant formulas | |
Tang et al. | Nutrient requirements of infants and young children | |
EP2719292B1 (en) | Medical nutrition product intended for being administered to obese persons recently operated in bariatric surgery | |
Hoffman et al. | Protein supplementation and athlete performance | |
Socha | Metabolic Programming, Breastfeeding And Later Risk Of Obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NESTEC S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLANCHER, FLORENCE;MACE, CATHERINE;SHAHKHALILI DULLOO, YASSAMAN;SIGNING DATES FROM 20131205 TO 20131213;REEL/FRAME:042958/0524 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: MERGER;ASSIGNOR:NESTEC S.A.;REEL/FRAME:049391/0756 Effective date: 20190528 |
|
AS | Assignment |
Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNOR:NESTEC S.A.;REEL/FRAME:049853/0398 Effective date: 20190528 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912;ASSIGNOR:NESTEC S.A.;REEL/FRAME:054082/0001 Effective date: 20190528 Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912;ASSIGNOR:NESTEC S.A.;REEL/FRAME:054082/0165 Effective date: 20190528 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |